• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

In vivo CAR-T exhibits activity in advanced multiple myeloma

by Mark Leiser | Dec 15, 2025 | Uncategorized

ORLANDO — An in vivo chimeric antigen receptor T-cell therapy administered without lymphodepletion exhibited activity among patients with advanced multiple myeloma, according to findings presented at ASH Annual Meeting and Exposition.The first four patients treated...

by MM360 Staff | Dec 10, 2025 | Uncategorized

Source: CURE articles Post Content Read More

by MM360 Staff | Dec 10, 2025 | Uncategorized

Source: CURE articles Post Content Read More

Teclistamab combo improves relapsed, refractory myeloma outcomes

by Josh Friedman | Dec 9, 2025 | Uncategorized

ORLANDO — “The best PFS results we’ve ever seen in relapsed, refractory myeloma.”The combination of teclistamab (Tecvayli, Janssen) plus daratumumab (Darzalex, Johnson & Johnson/Janssen) reduced the risk for disease progression or death 83% from standard...

by MM360 Staff | Dec 9, 2025 | Uncategorized

Source: CURE articles Post Content Read More

by MM360 Staff | Dec 7, 2025 | Uncategorized

Source: CURE articles Post Content Read More
« Older Entries

Recent Content

  • Preclinical evaluation of TIGIT as a target to enhance efficacy and mitigate T cell exhaustion in multiple myeloma following BCMA-CAR-T therapy
  • Dynamics of clonal hematopoiesis and cellular responses to stress-induced toxicity in autologous stem cell transplantation
  • Prognostic value of serological and PET/CT response kinetics in patients with multiple myeloma treated with BCMA CAR-T
  • Author Correction: Microbiota-reprogrammed phosphatidylcholine inactivates cytotoxic CD8 T cells through UFMylation via exosomal SerpinB9 in multiple myeloma
  • Pancreatic cancer treatment atebimetinib set for Phase 3 trial
  • Toward functional cure in relapsed/refractory multiple myeloma: long-term outcomes from CARTITUDE-1 study cement the role of CAR-T cells
  • 1st trial participant receives Alpha DaRT radiation therapy for glioblastoma
  • (no title)
  • New targeted cancer therapy IDE034 heading to Phase 1 clinical trial
  • (no title)
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT